Pd01-05 Analyzing the Percentage of Positive 68ga-Psma-Pet/Ct Scans Based on Psa Ranges Across Distinct Indications for the Scan

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I (PD01)1 May 2024PD01-05 ANALYZING THE PERCENTAGE OF POSITIVE 68GA-PSMA-PET/CT SCANS BASED ON PSA RANGES ACROSS DISTINCT INDICATIONS FOR THE SCAN Shayan Ahmad, Maya N. Ataya, Clint D. Bahler, Michael O. Koch, Mark A. Green, Mark Tann, Ethan L. Ferguson, and Heather L. Huelster Shayan AhmadShayan Ahmad , Maya N. AtayaMaya N. Ataya , Clint D. BahlerClint D. Bahler , Michael O. KochMichael O. Koch , Mark A. GreenMark A. Green , Mark TannMark Tann , Ethan L. FergusonEthan L. Ferguson , and Heather L. HuelsterHeather L. Huelster View All Author Informationhttps://doi.org/10.1097/01.JU.0001009540.33579.43.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET) is an imaging technique used to identify patients with biochemically recurrent (BCR) prostate cancer and determine their plan of treatment. This study aims to analyze the percentage of positive PSMA-PET scans based on prostate specific antigen (PSA) ranges and the indications for the scans. METHODS: A retrospective analysis was conducted on a cohort of 347 patients, with BCR prostate cancer, who underwent PSMA-PET scans at Indiana University Hospital from May 2017 to November 2021. These scans were categorized into 4 different groups according to their indications: BCR post prostatectomy, BCR post radiation, BCR post prostatectomy and radiation, and Stage 4, defined as patients who had chemotherapy, CRPC, or evidence of distant metastasis. The results of the PSMA-PET scans were documented, the PSA values were divided into distinct ranges for each indication, and the percentage of positive scans for each range was evaluated. RESULTS: The probability of having a positive scan was 60% for patients with BCR post prostatectomy, 86.3% for patients with post radiation, 67.1% post prostatectomy and salvage radiation, and 95% for stage 4. Furthermore, when PSA values were stratified into different ranges, an increasing trend in the probability of positive scans was seen with rising PSA values for patients in the BCR post prostatectomy, and BCR post radiation groups. A threshold PSA value of 1 was observed for patients in stage 4, above which 100% of the scans were positive. Interestingly, across all indications, a PSA value of 10 or higher was almost certain to yield a positive scan, with the only exception being a patient in the BCR post prostatectomy and radiation group. Positive scans for a PSA value of0.2 resulted in a positive scan greater than 50% of the time. CONCLUSIONS: This study illustrates the relationship between the PSA values and the probability of a positive PSMA-PET scan according to the indication for the scan. From this we can conclude that stage 4 has the highest probability of a positive scan. In addition, in the majority of scans, a PSA of greater than 10 was associated with being 100% positive. Source of Funding: Telix Pharmaceuticals and Al Christy Prostate Cancer Foundation © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e64 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Shayan Ahmad More articles by this author Maya N. Ataya More articles by this author Clint D. Bahler More articles by this author Michael O. Koch More articles by this author Mark A. Green More articles by this author Mark Tann More articles by this author Ethan L. Ferguson More articles by this author Heather L. Huelster More articles by this author Expand All Advertisement PDF downloadLoading ...